sábado, 5 de marzo de 2016

NCTR Publications > NCTR Research Highlights

NCTR Publications > NCTR Research Highlights

National Center for Toxicological Researh log with FDA on left side

Current Highlight from February 26, 2016

Developments for Early Detection of Doxorubicin Cardiotoxicity
Collaborating scientists from NCTR, the National Cancer Institute, Korea University, and UltraPath Imaging have identified a panel of 61 energy metabolism and apoptosis genes from doxorubicin (DOX)-treated mice that are differentially expressed in heart mitochondria prior to and after evidence of drug-induced cardiac injury. This suggests the genes may be used as potential early indicators of cardiotoxicity.  Some of the 61 genes were differentially expressed at all cumulative dose levels (6-24 mg/kg DOX) administered at 3 mg/kg/week.  Plasma levels of cardiac troponin T (cTnT) increased at 18 and 24 mg/kg cumulative DOX dosages and frank cardiac injury was detected by pathology assessment at the high, 24 mg/kg dose.  The cardioprotectant drug, dexrazoxane, significantly reduced gene expression alteration and cTnT plasma levels, and eliminated cardiac pathology at the high dose.  DOX is an effective chemotherapeutic that is limited by an average lifetime-dose toxicity. Early biomarkers of drug-induced cardiotoxicity could enable an individualized approach to chemotherapeutic treatment.  Information about the study is available online at Toxicology and Applied Pharmacologydisclaimer icon.
For additional information, please contact Varsha Desai, Ph.D., Division of Systems Biology, FDA/NCTR.

No hay comentarios:

Publicar un comentario